A drug called givastomig produced a 77% response rate in gastric cancer. The stock trades 71% below its 52-week high. Sometimes the data and the price tell two different stories.
AIM ImmunoTech Doses Final Patient in Phase 2 Pancreatic Cancer Trial Ahead of Schedule
AIM ImmunoTech (NYSE American: AIM) had a busy stretch in the middle of this window. On June 15, the company announced it had regained compliance with NYSE American listing standards, resolving a prior stockholder equity deficiency. Three days later, on June 18, the final subject in the Phase 2 DURIPANC trial received their first dose, more than a month ahead of the original target.
DURIPANC tests Ampligen (rintatolimod) — a double-stranded RNA molecule that activates the TLR3 immune pathway — combined with AstraZeneca’s Imfinzi (durvalumab) in patients with metastatic pancreatic cancer who have stable disease after standard FOLFIRINOX chemotherapy. It is an investigator-initiated study run jointly by AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands.
The timeline now: primary endpoint analysis, Clinical Benefit Rate (the proportion of patients achieving stable disease, partial response, or complete response at 24 weeks after starting combination therapy), begins in December 2026. Topline results are expected Q1 2027. Secondary endpoint analysis follows roughly a year after the final patient’s first dose.
Two financings sit just outside and just inside this window worth knowing about. A $2.4 million registered direct and private placement closed May 20. A $2.65 million at-market offering under NYSE American rules priced June 9. Both are dilutive raises for a company that needed to resolve a listing deficiency the same month. The clinical milestone is real and ahead of schedule. The balance sheet work behind it is the part that does not show up in a press release headline. Filings on SEC EDGAR.
NovaBridge Biosciences Earns FDA Fast Track for Gastric Cancer Bispecific Antibody
NovaBridge Biosciences (Nasdaq: NBP) announced on June 16 that the FDA granted Fast Track Designation to givastomig, combined with nivolumab and chemotherapy, for previously untreated HER2-negative metastatic gastroesophageal adenocarcinoma in patients whose tumors are both CLDN18.2 and PD-L1 positive.
Givastomig is a CLDN18.2 x 4-1BB bispecific antibody (an engineered antibody that binds a tumor-specific protein on one arm and a T-cell activation receptor on the other, designed to trigger an immune attack specifically where the tumor marker is present rather than throughout the body). Phase 1b dose expansion data showed a 77% objective response rate at the 8 mg/kg dose and 73% at 12 mg/kg: numbers well above historical benchmarks for first-line gastric cancer chemotherapy alone.
A registrational Phase 3 trial is planned to begin as early as Q4 2026. The FDA separately confirmed givastomig’s potential eligibility for the accelerated approval pathway following a Type B meeting earlier this year. NovaBridge develops givastomig through a 50/50 global partnership with ABL Bio, excluding Greater China and South Korea.
The stock closed near $1.47 on the Fast Track news, down more than 71% from its 52-week high and trading below its 200-day moving average. NovaBridge was formerly known as I-Mab before its name change. The company also carries VIS-101, a retinal disease candidate heading into Phase 2b in H2 2026, and two earlier-stage bispecific antibodies, ragistomig and uliledlimab. Filings on SEC EDGAR.
Upcoming Catalysts: AIM Primary Endpoint Analysis, NovaBridge Phase 3 Start, Givastomig Conference Data
AIM ImmunoTech: Clinical Benefit Rate analysis begins December 2026. Topline DURIPANC results are expected Q1 2027. Any update on cash position ahead of that readout matters as much as the clinical data itself.
NovaBridge: detailed Phase 1b data for givastomig is expected at a major medical conference in H2 2026. The registrational Phase 3 start, targeted as early as Q4 2026, is the next structural milestone.
Sources
- GlobeNewswire: AIM ImmunoTech regains NYSE American compliance, June 15, 2026
- GlobeNewswire / BioSpace: AIM ImmunoTech final DURIPANC subject dosed, June 18, 2026
- GlobeNewswire: AIM ImmunoTech $2.65 million at-market financing, June 9, 2026
- GlobeNewswire / BioSpace: NovaBridge Biosciences FDA Fast Track givastomig, June 16, 2026
- CancerNetwork: Givastomig earns FDA Fast Track in HER2-negative gastric cancer, June 17, 2026
- StockTitan: NovaBridge NBP Fast Track news and stock technicals, June 16, 2026
Editorial Disclosure
This roundup is based entirely on publicly available information including press releases, SEC filings, and clinical trial disclosures. Securities discussed include AIM ImmunoTech Inc. (NYSE American: AIM) and NovaBridge Biosciences (Nasdaq: NBP). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. AIM ImmunoTech press release dates verified via GlobeNewswire and BioSpace: NYSE American compliance regained June 15, 2026; final DURIPANC patient dosed June 18, 2026; at-market financing priced June 9, 2026. NovaBridge press release date verified via GlobeNewswire, BioSpace, and CancerNetwork: Fast Track designation announced June 16, 2026. Ampligen, durvalumab in this combination, and givastomig are all investigational uses or combinations and have not been approved by the FDA for the indications discussed. AIM ImmunoTech previously disclosed a stockholder equity deficiency under NYSE American continued listing standards, which it has since resolved; the company has conducted multiple dilutive financings in 2026, including a $2.4 million raise in May and a $2.65 million at-market offering in June. DURIPANC primary endpoint analysis is not expected to begin until December 2026 and topline results are not expected until Q1 2027; no efficacy conclusions can be drawn at this time. NovaBridge’s givastomig Phase 1b data referenced in this article (77% and 73% objective response rates) are from an open-label, non-randomized, multi-center study without a concurrent control arm; cross-trial comparisons to historical chemotherapy benchmarks carry inherent limitations. A registrational Phase 3 trial for givastomig has not yet begun. These are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
